Soluble Urokinase Receptor as a Promising Marker for Early Prediction of Outcome in COVID-19 Hospitalized Patients

The Coronavirus disease 2019 (COVID-19), caused by SARS-CoV-2, has rapidly spread to become a global pandemic, putting a strain on health care systems. SARS-CoV-2 infection may be associated with mild symptoms or, in severe cases, lead patients to the intensive care unit (ICU) or death. The critical...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Filomena Napolitano, Gaetano Di Spigna, Maria Vargas, Carmine Iacovazzo, Biagio Pinchera, Daniela Spalletti Cernia, Margherita Ricciardone, Bianca Covelli, Giuseppe Servillo, Ivan Gentile, Loredana Postiglione, Nunzia Montuori
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	biomarkers COVID-19 suPAR sepsis ARDS complement system Medicine R
Acceso en línea:	https://doaj.org/article/c34d3a25e35340ffb4d2760e621aaffb
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:c34d3a25e35340ffb4d2760e621aaffb
record_format	dspace
spelling	oai:doaj.org-article:c34d3a25e35340ffb4d2760e621aaffb2021-11-11T17:33:26ZSoluble Urokinase Receptor as a Promising Marker for Early Prediction of Outcome in COVID-19 Hospitalized Patients10.3390/jcm102149142077-0383https://doaj.org/article/c34d3a25e35340ffb4d2760e621aaffb2021-10-01T00:00:00Zhttps://www.mdpi.com/2077-0383/10/21/4914https://doaj.org/toc/2077-0383The Coronavirus disease 2019 (COVID-19), caused by SARS-CoV-2, has rapidly spread to become a global pandemic, putting a strain on health care systems. SARS-CoV-2 infection may be associated with mild symptoms or, in severe cases, lead patients to the intensive care unit (ICU) or death. The critically ill patients suffer from acute respiratory distress syndrome (ARDS), sepsis, thrombotic complications and multiple organ failure. For optimization of hospital resources, several molecular markers and algorithms have been evaluated in order to stratify COVID-19 patients, based on the risk of developing a mild, moderate, or severe disease. Here, we propose the soluble urokinase receptor (suPAR) as a serum biomarker of clinical severity and outcome in patients who are hospitalized with COVID-19. In patients with mild disease course, suPAR levels were increased as compared to healthy controls, but they were dramatically higher in severely ill patients. Since early identification of disease progression may facilitate the individual management of COVID-19 symptomatic patients and the time of admission to the ICU, we suggest paying more clinical attention on patients with high suPAR levels.Filomena NapolitanoGaetano Di SpignaMaria VargasCarmine IacovazzoBiagio PincheraDaniela Spalletti CerniaMargherita RicciardoneBianca CovelliGiuseppe ServilloIvan GentileLoredana PostiglioneNunzia MontuoriMDPI AGarticlebiomarkersCOVID-19suPARsepsisARDScomplement systemMedicineRENJournal of Clinical Medicine, Vol 10, Iss 4914, p 4914 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	biomarkers COVID-19 suPAR sepsis ARDS complement system Medicine R
spellingShingle	biomarkers COVID-19 suPAR sepsis ARDS complement system Medicine R Filomena Napolitano Gaetano Di Spigna Maria Vargas Carmine Iacovazzo Biagio Pinchera Daniela Spalletti Cernia Margherita Ricciardone Bianca Covelli Giuseppe Servillo Ivan Gentile Loredana Postiglione Nunzia Montuori Soluble Urokinase Receptor as a Promising Marker for Early Prediction of Outcome in COVID-19 Hospitalized Patients
description	The Coronavirus disease 2019 (COVID-19), caused by SARS-CoV-2, has rapidly spread to become a global pandemic, putting a strain on health care systems. SARS-CoV-2 infection may be associated with mild symptoms or, in severe cases, lead patients to the intensive care unit (ICU) or death. The critically ill patients suffer from acute respiratory distress syndrome (ARDS), sepsis, thrombotic complications and multiple organ failure. For optimization of hospital resources, several molecular markers and algorithms have been evaluated in order to stratify COVID-19 patients, based on the risk of developing a mild, moderate, or severe disease. Here, we propose the soluble urokinase receptor (suPAR) as a serum biomarker of clinical severity and outcome in patients who are hospitalized with COVID-19. In patients with mild disease course, suPAR levels were increased as compared to healthy controls, but they were dramatically higher in severely ill patients. Since early identification of disease progression may facilitate the individual management of COVID-19 symptomatic patients and the time of admission to the ICU, we suggest paying more clinical attention on patients with high suPAR levels.
format	article
author	Filomena Napolitano Gaetano Di Spigna Maria Vargas Carmine Iacovazzo Biagio Pinchera Daniela Spalletti Cernia Margherita Ricciardone Bianca Covelli Giuseppe Servillo Ivan Gentile Loredana Postiglione Nunzia Montuori
author_facet	Filomena Napolitano Gaetano Di Spigna Maria Vargas Carmine Iacovazzo Biagio Pinchera Daniela Spalletti Cernia Margherita Ricciardone Bianca Covelli Giuseppe Servillo Ivan Gentile Loredana Postiglione Nunzia Montuori
author_sort	Filomena Napolitano
title	Soluble Urokinase Receptor as a Promising Marker for Early Prediction of Outcome in COVID-19 Hospitalized Patients
title_short	Soluble Urokinase Receptor as a Promising Marker for Early Prediction of Outcome in COVID-19 Hospitalized Patients
title_full	Soluble Urokinase Receptor as a Promising Marker for Early Prediction of Outcome in COVID-19 Hospitalized Patients
title_fullStr	Soluble Urokinase Receptor as a Promising Marker for Early Prediction of Outcome in COVID-19 Hospitalized Patients
title_full_unstemmed	Soluble Urokinase Receptor as a Promising Marker for Early Prediction of Outcome in COVID-19 Hospitalized Patients
title_sort	soluble urokinase receptor as a promising marker for early prediction of outcome in covid-19 hospitalized patients
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/c34d3a25e35340ffb4d2760e621aaffb
work_keys_str_mv	AT filomenanapolitano solubleurokinasereceptorasapromisingmarkerforearlypredictionofoutcomeincovid19hospitalizedpatients AT gaetanodispigna solubleurokinasereceptorasapromisingmarkerforearlypredictionofoutcomeincovid19hospitalizedpatients AT mariavargas solubleurokinasereceptorasapromisingmarkerforearlypredictionofoutcomeincovid19hospitalizedpatients AT carmineiacovazzo solubleurokinasereceptorasapromisingmarkerforearlypredictionofoutcomeincovid19hospitalizedpatients AT biagiopinchera solubleurokinasereceptorasapromisingmarkerforearlypredictionofoutcomeincovid19hospitalizedpatients AT danielaspalletticernia solubleurokinasereceptorasapromisingmarkerforearlypredictionofoutcomeincovid19hospitalizedpatients AT margheritaricciardone solubleurokinasereceptorasapromisingmarkerforearlypredictionofoutcomeincovid19hospitalizedpatients AT biancacovelli solubleurokinasereceptorasapromisingmarkerforearlypredictionofoutcomeincovid19hospitalizedpatients AT giuseppeservillo solubleurokinasereceptorasapromisingmarkerforearlypredictionofoutcomeincovid19hospitalizedpatients AT ivangentile solubleurokinasereceptorasapromisingmarkerforearlypredictionofoutcomeincovid19hospitalizedpatients AT loredanapostiglione solubleurokinasereceptorasapromisingmarkerforearlypredictionofoutcomeincovid19hospitalizedpatients AT nunziamontuori solubleurokinasereceptorasapromisingmarkerforearlypredictionofoutcomeincovid19hospitalizedpatients
_version_	1718432087104552960

Soluble Urokinase Receptor as a Promising Marker for Early Prediction of Outcome in COVID-19 Hospitalized Patients

Ejemplares similares